BCRX
BioCryst Pharmaceuticals, Inc.NASDAQHealthcare$9.02-3.84%ClosedMarket Cap: $1.89B
As of 2026-04-06
Valuation
P/E (TTM)
7.18
PEG
0.02
P/B
-15.97
P/S
2.16
EV/EBITDA
6.49
DCF Value
$-125.97
FCF Yield
17.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.7%
Operating Margin
39.0%
Net Margin
30.2%
ROE
-76.5%
ROA
51.3%
ROIC
93.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $406.6M | 97.6% | $260.4M | $245.8M | $1.12 | — |
| FY 2025 | $874.8M | 97.8% | $341.0M | $263.9M | $1.21 | — |
| Q3 2025 | $159.4M | 98.4% | $29.6M | $12.9M | $0.06 | — |
| Q2 2025 | $163.4M | 98.3% | $29.8M | $5.1M | $0.02 | — |
| Q1 2025 | $145.5M | 96.9% | $21.2M | $32.0K | $0.00 | — |
| Q4 2024 | $131.5M | 95.3% | $-4.5M | $-26.8M | $-0.13 | — |
| FY 2024 | $450.7M | 97.2% | $-2.5M | $-88.9M | $-0.43 | — |
| Q3 2024 | $117.1M | 97.2% | $7.7M | $-14.0M | $-0.07 | — |
| Q2 2024 | $109.3M | 98.4% | $8.8M | $-12.7M | $-0.06 | — |
| Q1 2024 | $92.8M | 98.6% | $-14.5M | $-35.4M | $-0.17 | — |
| Q4 2023 | $93.4M | 98.2% | $-42.7M | $-61.7M | $-0.31 | — |
| FY 2023 | $331.4M | 98.6% | $-103.7M | $-226.5M | $-1.18 | — |